Pharmacokinetics and Pharmacodynamics of Edivoxetine (LY2216684), a Norepinephrine Reuptake Inhibitor, in Pediatric Patients with Attention-Deficit/ Hyperactivity Disorder

• Published in: Journal of child and adolescent psychopharmacology Vol. 22; no. 4; pp. 269 - 276
• Main Authors: Kielbasa, William, Quinlan, Tonya, Jin, Ling, Xu, Wen, Lachno, D. Richard, Dean, Robert A., Allen, Albert J.
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.08.2012
• Subjects: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - pharmacokinetics; Adrenergic Uptake Inhibitors - pharmacology; Age Factors; Area Under Curve; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactivity disorder; Child; Children & youth; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug therapy; Female; Half-Life; Humans; Male; Morpholines - administration & dosage; Morpholines - pharmacokinetics; Morpholines - pharmacology; Pharmacology; Phenylethyl Alcohol - administration & dosage; Phenylethyl Alcohol - analogs & derivatives; Phenylethyl Alcohol - pharmacokinetics; Phenylethyl Alcohol - pharmacology; Tandem Mass Spectrometry; Tissue Distribution

Edivoxetine (LY2216684) is a selective and potent norepinephrine reuptake inhibitor (NERI). The pharmacokinetics (PK) and pharmacodynamics (PD) of edivoxetine were assessed in children and adolescent patients with attention-deficit/hyperactivity disorder (ADHD) following single and once-daily oral d...